| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/03/2005 | US20050026831 inhibitors of notch signalling comprising proteins or polypeptides having notch ligand domains, multimeric proteins or polynucleotide codes for the protein or polypeptides, used in the treatment of cancer; vaccines |
| 02/03/2005 | US20050026830 Compositions and methods for treating fibrosis |
| 02/03/2005 | US20050026825 Receptor |
| 02/03/2005 | US20050026823 Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| 02/03/2005 | US20050026289 Virus clearance of neoplastic cells from mixed cellular compositions |
| 02/03/2005 | US20050026287 Formulation of stabilized cationic transfection agent (s) /nucleic acid particles |
| 02/03/2005 | US20050026286 Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells |
| 02/03/2005 | US20050026283 Using electric field modification to transfer components across cell barriers; organelle transfer; in vitro fertility |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026252 Expression vector comprising rodent regulatory sequences for use as gene expression control tools in genetic engineering |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026228 Using concentration of receptor protein tyrosine kinase polypeptide/adaptor complex as diagnostic indicator of cell proliferative disorders; turmor diagnosis and treatment |
| 02/03/2005 | US20050026226 Serum Paraoxonase |
| 02/03/2005 | US20050026204 Using ligase conjugated probe as tool in identifying and joining preferential nucleotide sequences; circulization of probes in presence of target nucleotide sequences |
| 02/03/2005 | US20050026194 Using overexpression of relaxin-3 and somatostatin and angiotensin-like peptide receptor (SALPR) as diagnostic indicator of cell proliferative disorders |
| 02/03/2005 | US20050026182 Human CDNAS and proteins and uses thereof |
| 02/03/2005 | US20050026157 Enzymatic fusion protein comprising cleavage and nuclear localization domain for use gene targeting tool in gene therapeutics |
| 02/03/2005 | US20050026149 Expression vector comprising chimeric nucleotide comprising nuclear, choloroplast and/or mitochondrial localization signals for use as tools in transfer of heterologous genes into preferential genomes |
| 02/03/2005 | US20050026139 Generating transgenic cell comprising expression vector coding apotosis inducing factor for use in treatment of cell proliferative and viral disorders |
| 02/03/2005 | US20050026137 Expression vector comprising nucleotide sequences coding multimeric nuclear anchoring-protein for use as tool in transfer, expression and propagation of heterologous gene sequences |
| 02/03/2005 | US20050025838 Conditioned compositions for tissue restoration |
| 02/03/2005 | US20050025821 Lipid-comprising drug delivery complexes and methods for their production |
| 02/03/2005 | US20050025820 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| 02/03/2005 | US20050025815 Protonated/acidified nucleic acids are effective as bactericidal and/or bacteriostatic agents |
| 02/03/2005 | US20050025776 Vascular inflammatory disorders, atherosclerosis, arteritis or reperfusion injury, autoimmune, nervous system and connective tissue disorders, rheumatoid arthritis, meningitis, multiple sclerosis, inflammatory bowel disorders, ulcerative colitis and Crohn's disease |
| 02/03/2005 | US20050025753 Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells |
| 02/03/2005 | US20050025749 Grafting heart tissue; closure of heart defect |
| 02/03/2005 | US20050025746 Delivering an adeno-associated virus vector comprising a nucleotide sequence encoding glutamic acid decarboxylase to cells in specific areas of the brain; Parkinson's Disease, Alzheimer's Disease, Amyloid Lateral Sclerosis, and epilepsy |
| 02/03/2005 | US20050025745 Using a Bifidobacterium as a gene delivery vector for a recombinant DNA in combination with an antitumor agent to tumor tissues under anaerobic conditions |
| 02/03/2005 | US20050025742 Interferon or a gene delivery system encoding the interferon and SYN3 as delivery enhancing agent; protein or gene therapy; transurethral intravesical administration to epithelial cells; superficial bladder cancer |
| 02/03/2005 | CA2533858A1 Compositions and methods for treating cardiac dysfunction |
| 02/03/2005 | CA2533259A1 Acellular tissue matrices made from galactose .alpha.-1,3-galactose-deficient tissue |
| 02/03/2005 | CA2532926A1 Combined use of immunostimulatory oligonucleotides and cytokines or radiation |
| 02/03/2005 | CA2528043A1 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | CA2527369A1 Subgroup b adenoviral vectors for treating disease |
| 02/02/2005 | EP1502950A2 Method for purifying chemically modified RNA |
| 02/02/2005 | EP1502599A1 Active antiangiogenic therapy |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501931A2 Chimeric snrna molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501923A2 Pak5-related compositions and methods |
| 02/02/2005 | EP1501922A2 METHODS OF MODULATING HEME OXYGENASE−1 EXPRESSION AND TREATING HEME OXYGENASE−1 MEDIATED CONDITIONS |
| 02/02/2005 | EP1501860A2 Modulation of heat-shock-protein-based immunotherapies |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501853A2 RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/02/2005 | EP1501852A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 02/02/2005 | EP1501550A1 Non-viral gene delivery system |
| 02/02/2005 | EP1501548A1 Chemically activated carboxypolysaccharides and uses |
| 02/02/2005 | EP1501465A2 Vectors having both isoforms of beta-hexosaminidase |
| 02/02/2005 | EP1501359A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 02/02/2005 | EP1501357A2 Use of vegf for treating bone defects |
| 02/02/2005 | EP1501351A2 Short fragment homologous replacement to provide bse resistant cattle |
| 02/02/2005 | EP1221490B1 Recombinant adenoviral vectors and their utilization in the treatment of liver cirrhosis |
| 02/02/2005 | EP0981610B1 Compositions for treatment of disorders involving programmed cell death |
| 02/02/2005 | EP0966534B1 Compositions and methods for elimination of unwanted cells |
| 02/02/2005 | EP0862633B1 Virus protein antigens of the jc virus |
| 02/02/2005 | EP0851769B1 Gene therapy using ovine adenoviral vectors |
| 02/02/2005 | EP0832227B1 Method for prolonging the expression of a gene of interest using soluble ctla4 molecules |
| 02/02/2005 | EP0613495B1 Transgenic non-human animals lacking prion proteins |
| 02/02/2005 | CN1575340A Compositions and methods for treating neurodegenerative diseases |
| 02/02/2005 | CN1575337A Mammalian receptor proteins; related reagents and methods |
| 02/02/2005 | CN1575301A Administration of nucleic acid sequence to female animal |
| 02/02/2005 | CN1572875A Anti-SARS vaccine |
| 02/02/2005 | CN1572797A Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| 02/02/2005 | CN1572328A Vaccine against SARS virogene and its preparation method and use |
| 02/02/2005 | CN1572327A Preparation of vaccine against tumor using differential library and its use |
| 02/02/2005 | CN1187453C Cell lines for propagation of mutated herpes viruses |
| 02/02/2005 | CN1187370C Connective tissue growth factor fragments and methods and uses thereof |
| 02/02/2005 | CN1187095C Encapsulated cells capable of producing viral particles |
| 02/01/2005 | US6849718 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 02/01/2005 | US6849717 Polycystic kidney disease gene homologs required for male mating behavior in nematodes and assays based thereon |
| 02/01/2005 | US6849715 Agents useful for inactivation of Ras subfamily proteins |
| 02/01/2005 | US6849612 Oligonucleotide modulation of cell adhesion |
| 02/01/2005 | US6849611 Implantation of biological pacemaker that is molecularly determined |
| 02/01/2005 | US6849454 Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
| 02/01/2005 | US6849446 Genetic engineering |
| 02/01/2005 | US6849438 Isolated and purified human soluble guanylyl cyclase α1/β1 (hsgcα1/β1) |
| 02/01/2005 | US6849421 Nucleotide sequences coding enzymatic polypeptide for the use in the treatment of nervous system disorders |
| 02/01/2005 | US6849420 Isolated autophosphorylating polypeptide, possessing PI3 kinase (phosphoinositide-3 kinase) activity; use drug screening for regulators of cell motility, such as antimetastasis agents |
| 02/01/2005 | US6849413 Comprises peptidoglycan recognition protein (PGRP) for diagnosis and treatment of blood and tumor disorders |
| 02/01/2005 | US6849405 Incorporated into expression vectors to enhance recombinant protein production |
| 02/01/2005 | US6849261 CD4-independent HIV envelope proteins as vaccines and therapeutics |
| 02/01/2005 | US6849257 Comprises catalytic or stoichiometric lipid removal, wherein proteins and/or polypeptides (lysosoymal acid lipase) target receptors in and/or on the cell which lead to uptake into the lysosome |
| 02/01/2005 | CA2459622A1 Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
| 02/01/2005 | CA2325351C Non-stochastic generation of genetic vaccines and enzymes |
| 01/27/2005 | WO2005008248A2 Diagnosis and treatment of cervical cancer |
| 01/27/2005 | WO2005007877A2 Regulatable promoters for synthesis of small hairpin rna |
| 01/27/2005 | WO2005007849A1 Method of enhancing alkylating drug sensitivity |
| 01/27/2005 | WO2005007832A2 System for external control of oncolytic virus replication |
| 01/27/2005 | WO2005007827A2 Avian adeno-associated virus vector |
| 01/27/2005 | WO2005007824A2 Mutants of vaccinia virus as oncolytic agents |
| 01/27/2005 | WO2005007819A2 Charge-dynamic polymers and delivery of anionic compounds |
| 01/27/2005 | WO2005007811A2 Injection of bone marrow-derived cells and medium for angiogenesis |
| 01/27/2005 | WO2005007623A2 Inhibition of syk kinase expression |
| 01/27/2005 | WO2005007199A1 COMPOUNDS AND METHODS FOR DOWNREGULATING THE EFFECTS OF TGF-β |
| 01/27/2005 | WO2005007196A2 Lipid encapsulated interfering rna |
| 01/27/2005 | WO2005007186A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | WO2005007175A2 Cadherin directed molecular and cellular localization |
| 01/27/2005 | WO2005007109A2 Methods and compositions for cancer therapy using a novel adenovirus |
| 01/27/2005 | WO2005007108A2 Asymmetric disulfides and methods of using same |